Cyclic dipeptide
No FDA-approved product identified for this exact research entry in the targeted review.
A six-month study in 38 people with type 2 diabetes and vascular complications reported improvements in several clinical and biomarker measures. Its uncontrolled, sequential-cohort design cannot establish that cGP caused those changes.1
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed7
No numerical human elimination estimate was verified for the exact material in this review.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
A six-month study in 38 people with type 2 diabetes and vascular complications reported improvements in several clinical and biomarker measures. Its uncontrolled, sequential-cohort design cannot establish that cGP caused those changes.1
Reference sequence: clarity; cognition; metabolic/protective effects; IGF regulation. No validated human benefit timeline; nasal claims concern research models.7
These are reported timelines, not a prediction of your response.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OralOral supplement | 20–25 mcg natural cGP | Daily | Exploratory vascular-complication outcomes38 adults with type 2 diabetes and vascular complicationsHuman study | Six months | 1 |
Population 38 adults with type 2 diabetes and vascular complications Context Sequentially allocated cohorts; no placebo-controlled efficacy conclusion. Source dose wording 20–25 micrograms or 40–45 micrograms of natural cGP | |||||
| OralOral supplement | 40–45 mcg natural cGP | Daily | Exploratory vascular-complication outcomes38 adults with type 2 diabetes and vascular complicationsHuman study | Six months | 1 |
Population 38 adults with type 2 diabetes and vascular complications Context Sequentially allocated cohorts; no placebo-controlled efficacy conclusion. Source dose wording 20–25 micrograms or 40–45 micrograms of natural cGP | |||||
| OralOral (capsule) | 20-40 μg | 1x daily | General cognitive supportReference report | 4-12 weeks or continuous | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (capsule) | 40-50 μg | 1x daily | Neuroprotection/anti-agingReference report | 4-12 weeks or continuous | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (capsule) | 40-100 μg | 1x daily | Metabolic/cardiovascular supportReference report | 4-12 weeks or continuous | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (capsule) | 300 mg BCA | 2x daily | Via blackcurrant extractReference report | 4-12 weeks or continuous | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| IntranasalNasal | Varies by study | 1x daily | Research applicationReference report | 28 days in research studies | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Morning preferred, with or without food
Morning typically used in research
The small study cannot establish uncommon harms or long-term safety.
1Natural supplement composition and exposure cannot be assumed equivalent to research powder.
1Allergy, glucose changes, weakness, fatigue, nasal irritation or new neurological symptoms need assessment.
Endogenous origin does not establish supplement safety; long-term and nasal human data limited.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Combined IGF-axis effects.7
Reference report · Pep-Pedia label: Monitor CombinationBinding/regulatory rationale.7
Reference report · Pep-Pedia label: SynergisticProposed IGF-1/tissue-repair complement; untested.7
Reference report · Pep-Pedia label: CompatibleReported cognition pairing through different proposed pathways; untested.7
Reference report · Pep-Pedia label: CompatibleReported IGF-1/anxiety pairing; untested.7
Reference report · Pep-Pedia label: CompatibleNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.2
Research contextNo matching interactions. Try another name or filter.
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.2
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
The oral section describes capsules or blackcurrant-derived products.
The nasal section describes a saline-based research formulation.
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Results from a natural supplement do not validate purified injectable cGP or a general cognition indication.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Cyclic glycine-proline is studied in IGF-related biology, brain disorders and vascular function. Small studies of cGP-containing supplements need to be distinguished from purified-compound studies.
No FDA-approved product identified for this exact research entry in the targeted review.
2 amino acids (cyclic) · 154.17 Da
cyclo(Gly-Pro)Reference description; checked chemical identity takes precedence when available.7
Proposed competition at IGFBP-3 and downstream IGF signaling; receptor/BDNF claims need separate confirmation.7
A six-month study in 38 people with type 2 diabetes and vascular complications reported improvements in several clinical and biomarker measures. Its uncontrolled, sequential-cohort design cannot establish that cGP caused those changes.
1Vascular complications research. A six-month study in 38 people with type 2 diabetes and vascular complications reported improvements in several clinical and biomarker measures. Its uncontrolled, sequential-cohort design cannot establish that cGP caused those changes.1
Neurological. Memory, cognition, oxidative injury, Alzheimer models and Parkinson-related observations.7
Metabolic. IGF bioavailability, diabetes/vascular complications and blood pressure.7
Recovery / aging. Stroke associations, rat task learning and cognitive-aging biomarkers; association is not treatment benefit.7
Nasal research. Alzheimer mouse findings do not establish human nose-to-brain efficacy.7
Pep-Pedia discusses vascular and cognitive research.2
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Added the 2025 exploratory natural-supplement study in type 2 diabetes; it does not validate purified injectable cGP.
AI-prepared summaries. Independent medical editorial review is pending.
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source displays “36 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
Original sources and review status. Open a reference to read its summary.
Thirty-eight patients received natural cGP supplementation for six months in sequentially allocated cohorts. Reported improvements are preliminary because allocation was not randomized and there was no placebo group.
A six-month study in 38 people with type 2 diabetes and vascular complications reported improvements in several clinical and biomarker measures. Its uncontrolled, sequential-cohort design cannot establish that cGP caused those changes.
Additional research · Checked 2026-10-12
Secondary editorial profile and reported practices; not clinical validation.
Pep-Pedia reports: Treated mice had better spatial memory and lower plaque densities: hippocampus 42.3 to 14.5 and cortex 42.7 to 15.4 plaques/mm².
Reported population / model
APP/PS1 mice
Reported study details
20 mg/kg intranasal · 28 days
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Higher cGP/IGF-1 ratios were associated with better stroke or memory outcomes; these observations do not show supplementation causes benefit.
Reported population / model
Review
Reported study details
Multiple clinical observations · cGP/IGF-1 ratio analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Eleven Parkinson's patients receiving blackcurrant supplements had 74% higher CSF cGP and lower anxiety/depression scores; this was not isolated cGP treatment.
Reported population / model
Human subjects
Reported study details
11 PD patients · 28 days blackcurrant supplementation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Cell and animal experiments linked cGP/IGF-1 ratios to IGFBP-3 binding and the amount of free IGF-1.
Reported population / model
Cell culture & animal models
Reported study details
Various concentrations · IGFBP-3 binding analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12